India, June 19 -- The article outlines the significance of the deal and the outlook of the company, which specializes in developing branded generics, specialty drugs, and OTC products, with a primary focus on the therapeutic areas of dermatology, respiratory, and oncology.

With a market capitalization of Rs 60,870 crore, Glenmark Pharmaceuticals Ltd's share closed at Rs 2,156 per share, up 0.95 from its previous day's close. The share of this company gave a return of 30 percent over the last year.

Brokerage View Investec maintains a Buy rating on Glenmark with a revised target price of Rs 2,750, implying around 27.5 percent upside from closing, supported by strong earnings visibility through FY30.

Growth Guidance Supports Long-Term Ear...